The main goal of this phase 1 clinical trial was to evaluate the safety of an autologous mesenchymal stem cell (MSC) application as therapy for drug-resistant symptomatic epilepsy in a one-center study. It is well known that drug-resistant symptomatic epilepsy is a dramatically invalidating disorder